About Zanubrutinib API
Therapeutic CategoryAnti-Cancer/ Oncology-pt
CAS Number
1691249-45-2
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking BTK, a protein that signals B-cells to grow and multiply, thereby inhibiting the proliferation and survival of malignant B cells
Indication
Zanubrutinib is indicated for the treatment of:
Chronic lymphocytic leukemia (CLL)
Small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia (WM)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
Relapsed or refractory follicular lymphoma (FL)
Related APIs
Enzalutamide-pt
Anti-Cancer/ Oncology-pt
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!